Supported by fiscal and monetary stimulus, the pace of vaccine distributions in western economies is largely dictating the speed of economic recovery. Inoculations in the UK and US are both proving that the economic rebound after lockdowns can be rapid, after China paved the way to recovery in Asia last year. This is reassuring for the European Union where many states, including France and Germany, have been forced to re-impose new restrictions.
Monitoring the global recoveryTuesday, 04/27/2021
The global economic recovery continued through March with more evidence of improving industrial activity and commerce. US retail sales recorded their second-largest rise in since 1992, and manufacturing expanded by an almost four-decade high.
Positive economic developments saw markets pricing in a return of inflation. Even the external shock of Archegos Capital Management’s stock sell-off late in the month was most notable in its failure to disrupt markets structurally.
Rising US treasury yields, reflecting expectations that interest rates would respond to the accelerating recovery, were contained by the Federal Reserve’s communications. The US central bank reminded investors that it is focused on the real economy, jobless rates and average inflation targeting and sees no reason to raise rates before 2023.
PMI COMPOSITE INDICES OF ECONOMIC ACTIVITY
Investor attention is poised to shift
March underlined again that 2021’s equity markets continue to be driven by macroeconomic reflation expectations, rather than stock-specific factors. In this environment, equities remain the most attractive asset class since the global recovery is fuelling earnings growth, offsetting any increases in fixed income yields. Indeed, the Fed has consistently reminded markets that it will tolerate rising yields as long as they are driven by the improving economic outlook, itself positive for equities.
As this recovery matures and we move into the first quarter’s reporting season we expect markets to become more responsive to stock-specific fundamentals, and so start to differentiate between sectors and firms. Investors’ attention will then return to sectors where there is appetite for more quality stocks, such as technology. Until then, we maintain our cyclical bias to sectorial and geographical equity allocations and remain cautious on fixed income assets, which are subject to upward pressures on long- term rates.
The pandemic has not exposed fragilities in the credit markets, supported as they are by central bank liquidity and governments’ fiscal policies. Corporations have used the opportunity to refinance at very favourable rates. And although high yield credit remains correlated to equity values, commercial lending has been supportive. We see no catalysts to change that for the moment.
We are not yet at the end of this reflation cycle, and do not yet see signs of returning to the longer-term ‘Japanification’ trend in the global economy. With the normalisation of interest rates and the end of monetary and fiscal stimulus still distant, it is certainly too early for radical portfolio adjustments.
This marketing document has been issued by the SYZ Group (hereinafter referred to as « SYZ »). It is not intended for distribution to or use by individuals or legal entities that are citizens of or reside in a state, country or jurisdiction in which applicable laws and regulations prohibit its distribution, publication, issue or use. Users are solely responsible for verifying that they are legally authorised to consult the information herein. This material is intended for informational purposes only and should not be construed as an offer or solicitation for the purchase or sale of any financial instrument, or as a contractual document. The information provided herein is not intended to constitute legal, tax, or accounting advice and may not be suitable for all investors. The market valuations, terms, and calculations contained herein are estimates only and are subject to change without notice. The information provided is believed to be reliable; however the SYZ Group does not guarantee its completeness or accuracy. Past performance is not an indication of future results.